Search 

The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.

The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Follow this page to stay up-to-date with the latest NIHR news, information and resources. If you're interested in information specific to the life sciences industry you may also want to follow NIHR Industry or if you're one the many researcher or health care professionals already working with us you may find the updates from NIHR Community of interest.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immuno diagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.

One Nucleus was formed in April 2010 by the merger of two regional lifescience networks – Cambridge-based ERBI and the London Biotechnology Network (LBN).  Together we form a commercial, clinical and academic powerhouse.  London and Cambridge are home to at least 60% of the UK’s life science industry base, four of the UK’s five Academic Health Science Centres and three of the world’s top six universities. The merger of ERBI and LBN recognises that the Cambridge-London network is an international life science “super cluster”.

Pangaea Data Limited have pioneered a product based on their novel unsupervised AI to unlock hidden value from unstructured textual health data, which comprises 80% of patient records and >90% of medical blogs and social media feeds. Pangaea’s product is used by scientists from the Biopharmaceutical industry to extract intelligence such as phenotypes (clinical features) so they can stratify patients effectively and find more patients for drug discovery, clinical trial and new product launches at scale, which is otherwise challenging, especially in the context of hard to diagnose conditions such as rare and chronic diseases where 60% of the patient population is not diagnosed properly. The company has access to more than 500 million patient electronic health records through its partnerships with hospitals and other such providers from the US, UK, Europe, South America and Asia Pacific.

Biopharmaceutical companies are also using the product to automatically generate clinical study reports and the likes from experimental data and to find adverse events for Pharmacovigilance purposes. Pangaea continually publish their work in high impact peer reviewed journals.

Pangaea is based in San Francisco, London and Hong Kong and was founded by experienced entrepreneurs who have raised more than £130 million through their academic research and is advised by leading experts from industry, Imperial College London and Stanford University.

Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

We focus on patients to reveal the complex personal biology of chronic diseases.

Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases.

Better understanding of complex disease biology -
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people.

Accurately defining sub-groups of patients -
Enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient.

New disease insights through collaboration -
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes.

We work with multi-disciplinary groups and organizations in disease collaborations to advance the understanding and treatment of chronic disease. Bring your data and expertise and work with our team and industry partners.

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and  integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.

Remap Consulting is a specialist pricing, reimbursement and market access consultancy offering an integrated, evidence-based approach to optimising market access. Our strength lies in our ability to understand the market access challenges from your perspective and to develop payer-focused solutions tailored to your business needs.

Our extensive pharmaceutical industry & consulting backgrounds within leading companies, encompasses expertise across the whole product lifecycle – from early R&D development through to patent expiry and beyond – enables us to understand the issue from your perspective and develop solutions accordingly.

Our clients are typically people responsible for the pricing and reimbursement of products who are asking:
- What is the optimal price for our product?
- Have we got the right evidence to support pricing and market access at launch?
- Do we have the right training capabilities in house to secure pricing and reimbursement?
- What is the pricing and market access potential for our business development opportunities?

Headquartered in Burlington, MA, for 40 years SEKISUI Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We continue to invest in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan. Our workforce spans six sites located in four countries. We are a sister company to SEKISUI Medical in Japan, making us a worldwide company with R&D and Manufacturing facilities on three continents. We develop, manufacture, and supply billions of tests each year to the global healthcare market through our commercial networks and partners.

Our product lines include:

• Clinical chemistry reagents

• Coagulation reagents

• Point-of-care rapid tests and immunoassay system

• Enzymes and specialty biochemicals